Daré Bioscience, Inc. (DARE)
Largest Insider Buys in Sector
DARE Stock Price History Chart
DARE Stock Performance
About Daré Bioscience, Inc.
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
Insider Activity of Daré Bioscience, Inc.
Over the last 12 months, insiders at Daré Bioscience, Inc. have bought $0 and sold $0 worth of Daré Bioscience, Inc. stock.
On average, over the past 5 years, insiders at Daré Bioscience, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 454,545 shares for transaction amount of $500,000 was made by HAWLEY ROGER (director) on 2019‑04‑11.
List of Insider Buy and Sell Transactions, Daré Bioscience, Inc.
| 2019-04-11 | director | 454,545 2.8482% | $1.10 | $500,000 | -22.94% | |||
| 2018-06-11 | director | 140,000 1.2031% | $1.45 | $203,378 | -35.81% | |||
| 2016-02-22 | director | 1,182 0.0043% | $2.09 | $2,468 | -32.54% | |||
| 2016-02-19 | director | 3,400 0.0125% | $2.08 | $7,058 | -27.67% | |||
| 2016-02-18 | director | 9,000 0.033% | $2.09 | $18,802 | -25.96% | |||
| 2016-02-17 | director | 8,920 0.0329% | $2.12 | $18,882 | -17.62% | |||
| 2016-02-16 | director | 9,000 0.0325% | $2.00 | $18,028 | -5.17% | |||
| 2016-02-12 | director | 8,622 0.0324% | $2.00 | $17,263 | +1.03% | |||
| 2016-02-11 | director | 8,700 0.0324% | $2.03 | $17,665 | -1.51% | |||
| 2016-02-10 | director | 9,000 0.0335% | $2.08 | $18,679 | -3.43% | |||
| 2016-02-09 | director | 9,000 0.0333% | $2.08 | $18,697 | -3.17% | |||
| 2016-02-08 | director | 9,000 0.0344% | $2.15 | $19,318 | -2.93% | |||
| 2016-02-05 | director | 9,000 0.033% | $2.29 | $20,651 | -11.79% | |||
| 2016-02-04 | director | 8,126 0.0294% | $2.31 | $18,761 | -13.09% | |||
| 2016-02-03 | director | 8,036 0.0294% | $2.27 | $18,262 | -10.57% | |||
| 2016-02-02 | director | 8,790 0.0331% | $2.37 | $20,818 | -11.30% | |||
| 2016-02-01 | director | 9,000 0.0329% | $2.37 | $21,328 | -13.50% | |||
| 2016-01-29 | director | 2,400 0.0088% | $2.40 | $5,772 | -14.17% | |||
| 2016-01-28 | director | 9,000 0.034% | $2.45 | $22,036 | -12.87% | |||
| 2016-01-27 | director | 9,000 0.0331% | $2.46 | $22,132 | -15.16% |
Insider Historical Profitability
| Crane Alan L | 4771739 54.8451% | $3.28 | 1 | 0 | ||
| Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 3262437 37.4976% | $3.28 | 1 | 0 | |
| VENROCK ASSOCIATES V LP | 10 percent owner | 3015017 34.6538% | $3.28 | 1 | 0 | |
| CVF, LLC | 10 percent owner | 2592577 29.7984% | $3.28 | 2 | 0 | |
| LILLY ELI & CO | 10 percent owner | 2356227 27.0819% | $3.28 | 1 | 0 | |
| Hall Steven Edward | 2356227 27.0819% | $3.28 | 1 | 0 | ||
| Lux Capital Management, LLC | 951999 10.942% | $3.28 | 1 | 0 | ||
| HAWLEY ROGER | director | 944956 10.8611% | $3.28 | 2 | 0 | <0.0001% |
| WALT DAVID R | director | 167491 1.9251% | $3.28 | 38 | 0 | |
| RASTETTER WILLIAM H | director | 60307 0.6932% | $3.28 | 1 | 0 |